MPM BioImpact
MPM BioImpact is a biotechnology investment firm that builds and funds companies across the drug development process to transform scientific breakthroughs into medicines. The firm combines 30+ years of MPM CAPITAL biotech investing with BioImpact’s public-investing experience, manages over $3 billion AUM across early-stage venture funds, private/public impact funds and a public equities fund, and reports outcomes including 60 FDA‑approved drugs and 120+ M&A and IPO events. MPM BioImpact uses Entrepreneur Partners and an active company-creation model to provide domain expertise, operational capabilities and strategic support to portfolio companies.
MPM BioImpact
Boston, Massachusetts, United States, North America
Services
Equity investment (private and public)
Provides capital through private and public equity funds, including early-stage venture funds, private/public impact funds, and a public equities fund.
Company creation and incubation
Builds new companies (company formation and early operational setup) and serves as a founding investor for therapeutics companies.
Strategic guidance and entrepreneur partnership
Provides domain expertise, regulatory strategy, clinical development guidance and executive recruitment via Entrepreneur Partners and investment professionals.
Operational and manufacturing support (via affiliated companies)
Supports portfolio companies with manufacturing and technology capabilities through affiliated or created companies (example: ElevateBio provides integrated manufacturing and next-generation technologies).
Network and strategic collaborations
Connects portfolio companies with industry partners, collaborators and strategic investors to advance development and commercialization (examples in portfolio news include collaborations and corporate financings).
Equity investment (private and public)
Provides capital through private and public equity funds, including early-stage venture funds, private/public impact funds, and a public equities fund.
Company creation and incubation
Builds new companies (company formation and early operational setup) and serves as a founding investor for therapeutics companies.
Strategic guidance and entrepreneur partnership
Provides domain expertise, regulatory strategy, clinical development guidance and executive recruitment via Entrepreneur Partners and investment professionals.
Operational and manufacturing support (via affiliated companies)
Supports portfolio companies with manufacturing and technology capabilities through affiliated or created companies (example: ElevateBio provides integrated manufacturing and next-generation technologies).
Network and strategic collaborations
Connects portfolio companies with industry partners, collaborators and strategic investors to advance development and commercialization (examples in portfolio news include collaborations and corporate financings).
Portfolio
Develops circular RNA (oRNA) and non-viral delivery; collaboration with Vertex Pharmaceuticals on sickle cell disease and transfusion-dependent beta thalassemia noted in news.
#RNA therapeutics (circular RNA)
Developing miniprotein actinium-conjugates (targeted alpha radiopharmaceuticals); raised significant financings (e.g., oversubscribed $175M Series B referenced).
#Radiopharmaceuticals / oncology
Combines manufacturing, next-generation technologies, and therapeutic development under one roof; referenced in collaborations and press.
#Cell, gene, and RNA therapy manufacturing and technologies
Translating a research breakthrough targeting HHLA2 into precision cancer therapies.
#Oncology (novel immunotherapies)
#Cell therapy / oncology
Closed a $53M Series E equity financing (April 27, 2023) per site news.
#Biotech / therapeutics
Develops circular RNA (oRNA) and non-viral delivery; collaboration with Vertex Pharmaceuticals on sickle cell disease and transfusion-dependent beta thalassemia noted in news.
#RNA therapeutics (circular RNA)
Developing miniprotein actinium-conjugates (targeted alpha radiopharmaceuticals); raised significant financings (e.g., oversubscribed $175M Series B referenced).
#Radiopharmaceuticals / oncology
Combines manufacturing, next-generation technologies, and therapeutic development under one roof; referenced in collaborations and press.
#Cell, gene, and RNA therapy manufacturing and technologies
Translating a research breakthrough targeting HHLA2 into precision cancer therapies.
#Oncology (novel immunotherapies)
#Cell therapy / oncology
Closed a $53M Series E equity financing (April 27, 2023) per site news.
#Biotech / therapeutics